{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:53:06Z","timestamp":1789239186854,"version":"build-2803163510"},"reference-count":112,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials. These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the currently employed regimens in multiple myeloma and compare clinical trials with real-life experiences. We also intend to put a spotlight on promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) which are proving to be effective in changing the course of advanced-stage disease.<\/jats:p>","DOI":"10.3390\/curroncol30110705","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T10:59:54Z","timestamp":1699009194000},"page":"9710-9733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multiple Myeloma in 2023 Ways: From Trials to Real Life"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-2640","authenticated-orcid":false,"given":"Manlio","family":"Fazio","sequence":"first","affiliation":[{"name":"Post-Graduation School of Haematology, University of Catania, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4405-2716","authenticated-orcid":false,"given":"Vittorio","family":"Del Fabro","sequence":"additional","affiliation":[{"name":"Division of Haematology and BMT, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziatina Laura","family":"Parrinello","sequence":"additional","affiliation":[{"name":"Division of Haematology and BMT, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-5676","authenticated-orcid":false,"given":"Uro\u0161","family":"Markovic","sequence":"additional","affiliation":[{"name":"Division of Haematology and BMT, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-4504","authenticated-orcid":false,"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u201cG. D\u2019Alessandro\u201d, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Accardi","sequence":"additional","affiliation":[{"name":"Department of Hematology I, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda Donatella","family":"Vincelli","sequence":"additional","affiliation":[{"name":"Haematology Unit, Haemato-Oncology and Radiotherapy Department, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-5155","authenticated-orcid":false,"given":"Salvatore","family":"Leotta","sequence":"additional","affiliation":[{"name":"Division of Haematology and BMT, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Elia","sequence":"additional","affiliation":[{"name":"Division of Haematology and BMT, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Esposito","sequence":"additional","affiliation":[{"name":"Post-Graduation School of Haematology, University of Catania, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-805X","authenticated-orcid":false,"given":"Bruno","family":"Garibaldi","sequence":"additional","affiliation":[{"name":"Post-Graduation School of Haematology, University of Catania, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sapuppo","sequence":"additional","affiliation":[{"name":"Post-Graduation School of Haematology, University of Catania, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Orofino","sequence":"additional","affiliation":[{"name":"Post-Graduation School of Haematology, University of Catania, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-4433","authenticated-orcid":false,"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[{"name":"Dipartimento di Specialit\u00e0 Medico-Chirurgiche, CHIRMED, Sezione di Ematologia, Universit\u00e0 degli Studi di Catania, 95131 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate \u201cG.F.Ingrassia\u201d, University of Catania, 95131 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Post-Graduation School of Haematology, University of Catania, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"},{"name":"Division of Haematology and BMT, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"},{"name":"Dipartimento di Specialit\u00e0 Medico-Chirurgiche, CHIRMED, Sezione di Ematologia, Universit\u00e0 degli Studi di Catania, 95131 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-3598","authenticated-orcid":false,"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[{"name":"Division of Haematology and BMT, A.O.U. \u2018Policlinico-San Marco\u2019, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3324\/haematol.2016.142737","article-title":"Innovations in treatment and response evaluation in multiple myeloma","volume":"101","author":"Wester","year":"2016","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2017.73.1331","article-title":"Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy","volume":"35","author":"Harousseau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12185-019-02615-z","article-title":"Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry","volume":"109","author":"Takamatsu","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_6","first-page":"1","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Mynott","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jelinek, T., Bezdekova, R., Zatopkova, M., Burgos, L., Simicek, M., Sevcikova, T., Paiva, B., and Hajek, R. (2018). Erratum: Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J., e621.","DOI":"10.1038\/bcj.2017.101"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: Cells\u2019 journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"J. Bone Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.122.264972","article-title":"New Developments in Myeloma Treatment and Response Assessment","volume":"64","author":"Jamet","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","article-title":"Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods","volume":"55","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Santoni, A., Simoncelli, M., Franceschini, M., Ciofini, S., Fredducci, S., Caroni, F., Sammartano, V., Bocchia, M., and Gozzetti, A. (2022). Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI. J. Pers. Med., 12.","DOI":"10.3390\/jpm12111885"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.6004\/jnccn.2021.5009","article-title":"Updates in the Treatment of Multiple Myeloma","volume":"19","author":"Kumar","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/14712598.2018.1544240","article-title":"CD38 as an immunotherapeutic target in multiple myeloma","volume":"18","author":"Bonello","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_20","first-page":"e528","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mor\u00e8, S., Corvatta, L., Manieri, V.M., Saraceni, F., Scortechini, I., Mancini, G., Fiorentini, A., Olivieri, A., and Offidani, M. (2022). Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. Cells, 11.","DOI":"10.3390\/cells11040606"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2021","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_26","first-page":"e23329","article-title":"Diagnosing Frailty in Primary Care Practice","volume":"14","author":"Somagutta","year":"2022","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2019","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"830922","DOI":"10.3389\/fonc.2022.830922","article-title":"Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting","volume":"12","author":"Bonello","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study","volume":"39","author":"Stege","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: Patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"643490","DOI":"10.3389\/fonc.2021.643490","article-title":"Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens","volume":"11","author":"Botta","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0583-7","article-title":"Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study","volume":"11","author":"Dimopoulos","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Bonello, F., Boccadoro, M., and Larocca, A. (2020). Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients. Cancers, 12.","DOI":"10.3390\/cancers12113106"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): Outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2020","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: Results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt","year":"2020","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","article-title":"Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: The randomized GMMG phase III trial ReLApsE","volume":"35","author":"Goldschmidt","year":"2021","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Baertsch, M.-A., Fougereau, M., Hielscher, T., Sauer, S., Breitkreutz, I., Jordan, K., M\u00fcller-Tidow, C., Goldschmidt, H., Raab, M.-S., and Hillengass, J. (2021). Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13184706"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Conticello, C., Romano, A., Del Fabro, V., Martino, E.A., Calafiore, V., Sapienza, G., Leotta, V., Parisi, M.S., Markovic, U., and Garibaldi, B. (2019). Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network. J. Clin. Med., 8.","DOI":"10.1097\/01.HS9.0000566976.32025.83"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1007\/s00277-020-04158-4","article-title":"KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: A retrospective survey in 123 patients","volume":"99","author":"Palmieri","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-020-04329-3","article-title":"Carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma patients: The real-life experience of Rete Ematologica Pugliese (REP)","volume":"100","author":"Mele","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1080\/10428194.2020.1802452","article-title":"A Daratumumab, lenalidomide, and dexamethasone combination in relapsed\/refractory myeloma patients: A real-life single-center experience","volume":"61","author":"Antonioli","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/jha2.359","article-title":"Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed\/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group","volume":"3","author":"Fazio","year":"2022","journal-title":"eJHaem"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed\/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_60","first-page":"E15","article-title":"Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis","volume":"98","author":"Dimopoulos","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody\u2013Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Condorelli, A., Garibaldi, B., Gagliano, C., Romano, A., del Fabro, V., Parrinello, N.L., Longo, A., Cosentino, S., Di Raimondo, F., and Conticello, C. (2021). Belantamab Mafodotin and Relapsed\/Refractory Multiple Myeloma: This Is Not Game Over. Acta Haematol., Online ahead of print.","DOI":"10.1159\/000521112"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000936252.25785.17","article-title":"P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL","volume":"7","author":"Nooka","year":"2023","journal-title":"HemaSphere"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_67","first-page":"E5","article-title":"Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs. standard of care in MAMMOTH","volume":"96","author":"Cornell","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40259-021-00514-6","article-title":"Targeting Nuclear Export Proteins in Multiple Myeloma Therapy","volume":"36","author":"Richard","year":"2022","journal-title":"BioDrugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ejh.13723","article-title":"Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients","volume":"108","author":"Morabito","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"624405","DOI":"10.3389\/fonc.2021.624405","article-title":"Daratumumab as Single Agent in Relapsed\/Refractory Myeloma Patients: A Retrospective Real-Life Survey","volume":"11","author":"Markovic","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-020-03323-6","article-title":"Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: A retrospective study from two academic centers","volume":"147","author":"Hose","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T Cell Toxicity: Current Management and Future Directions","volume":"3","author":"Perales","year":"2019","journal-title":"HemaSphere"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1182\/blood-2021-146072","article-title":"Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2","volume":"138","author":"Cohen","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: Comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e1220745","DOI":"10.1097\/01.HS9.0000970436.12207.45","article-title":"P883: Alnuctamab (ALNUC.; BMS-986349, CC-93269), A BCMA \u00d7 CD3 T-Cell Engager, in Patients (PTS) with Relapsed\/Refractory Multiple Myeloma (RRMM): Latest Results from a Phase 1 First-in-Human Clinical Study","volume":"7","author":"Wong","year":"2023","journal-title":"Hemasphere"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study","volume":"140","author":"Mazza","year":"2022","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Nath","year":"2023","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: Latest updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: A systematic literature review","volume":"12","author":"Beksac","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs","volume":"105","author":"Montefusco","year":"2019","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3109\/10428194.2013.853296","article-title":"Autologous stem cell transplant can overcome poor prognosis in patients with multiple myeloma with extramedullary plasmacytoma","volume":"55","author":"Li","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_89","first-page":"890","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2019.219295","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome","volume":"105","author":"Beksac","year":"2019","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Minarik, J., Pika, T., Radocha, J., Jungova, A., Straub, J., Jelinek, T., Pour, L., Pavlicek, P., Mistrik, M., and Brozova, L. (2021). Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer, 21.","DOI":"10.1186\/s12885-020-07732-1"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhou, X., Fl\u00fcchter, P., Nickel, K., Meckel, K., Messerschmidt, J., B\u00f6ckle, D., Knorz, S., Steinhardt, M.J., Krummenast, F., and Danhof, S. (2020). Carfilzomib Based Treatment Strategies in the Management of Relapsed\/Refractory Multiple Myeloma with Extramedullary Disease. Cancers, 12.","DOI":"10.3390\/cancers12041035"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0609.2011.01644.x","article-title":"Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma","volume":"87","author":"Alegre","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/16078454.2021.2019364","article-title":"Pomalidomide-based therapy for extramedullary multiple myeloma","volume":"27","author":"Li","year":"2022","journal-title":"Hematology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13217","article-title":"Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed \/ refractory multiple myeloma","volume":"102","author":"Granell","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_98","first-page":"832","article-title":"Extramedullary multiple myeloma escapes the effect of thalidomide","volume":"89","author":"Cibeira","year":"2004","journal-title":"Haematologica"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-019-03655-5","article-title":"Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: A real-life single-center retrospective study","volume":"98","author":"Jullien","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-140243","article-title":"Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease\u2014A Single Institution Observation in China","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-022-03636-9","article-title":"Five-year remission without disease progression in a patient with relapsed\/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: A case report","volume":"16","author":"Wang","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1.. Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)","volume":"39","author":"Usmani","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2022-157945","article-title":"Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial","volume":"140","author":"Richardson","year":"2022","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Phase 1\/2 Results from MonumenTAL-1","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.HS9.0000936368.13093.f4","article-title":"P60 EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20-YEARS SINGLE CENTER EXPERIENCE","volume":"7","author":"Palumbo","year":"2023","journal-title":"HemaSphere"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"101465","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-137118","article-title":"HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis","volume":"136","author":"Richardson","year":"2020","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: Ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2015","journal-title":"Neuro-Oncology"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/705\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:16:24Z","timestamp":1760130984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/11\/705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":112,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["curroncol30110705"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30110705","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]}}}